[go: up one dir, main page]

MXPA05010216A - Use of ritonavir for the treatment of unconjugated hyperbilirubinemia. - Google Patents

Use of ritonavir for the treatment of unconjugated hyperbilirubinemia.

Info

Publication number
MXPA05010216A
MXPA05010216A MXPA05010216A MXPA05010216A MXPA05010216A MX PA05010216 A MXPA05010216 A MX PA05010216A MX PA05010216 A MXPA05010216 A MX PA05010216A MX PA05010216 A MXPA05010216 A MX PA05010216A MX PA05010216 A MXPA05010216 A MX PA05010216A
Authority
MX
Mexico
Prior art keywords
ritonavir
treatment
ugt1a1
unconjugated hyperbilirubinemia
administering
Prior art date
Application number
MXPA05010216A
Other languages
Spanish (es)
Inventor
F Waring Jeffrey
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/395,772 external-priority patent/US20040192624A1/en
Priority claimed from US10/802,829 external-priority patent/US7320961B2/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MXPA05010216A publication Critical patent/MXPA05010216A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to a method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir. In particular, the present invention is directed to a method of treating unconjugated hyperbilirubinemia by UGT1A1 induction comprising the step of administering to a subject an effective amount of ritonavir.
MXPA05010216A 2003-03-24 2004-03-19 Use of ritonavir for the treatment of unconjugated hyperbilirubinemia. MXPA05010216A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/395,772 US20040192624A1 (en) 2003-03-24 2003-03-24 Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate
US10/802,829 US7320961B2 (en) 2003-03-24 2004-03-18 Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate
PCT/US2004/008415 WO2004084892A1 (en) 2003-03-24 2004-03-19 Use of ritonavir for the treatment of unconjugated hyperbilirubinemia

Publications (1)

Publication Number Publication Date
MXPA05010216A true MXPA05010216A (en) 2005-11-08

Family

ID=33100955

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010216A MXPA05010216A (en) 2003-03-24 2004-03-19 Use of ritonavir for the treatment of unconjugated hyperbilirubinemia.

Country Status (5)

Country Link
EP (1) EP1608366A1 (en)
JP (1) JP2007525432A (en)
CA (1) CA2517831A1 (en)
MX (1) MXPA05010216A (en)
WO (1) WO2004084892A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7320961B2 (en) 2003-03-24 2008-01-22 Abbott Laboratories Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04188068A (en) * 1990-11-22 1992-07-06 Eiken Chem Co Ltd Test piece for detecting bilirubin
JP3753761B2 (en) * 1995-07-25 2006-03-08 研正 岡本 Phototherapy equipment

Also Published As

Publication number Publication date
CA2517831A1 (en) 2004-10-07
EP1608366A1 (en) 2005-12-28
JP2007525432A (en) 2007-09-06
WO2004084892A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
SG147442A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
DE60215787D1 (en) TREATMENT OF TYPE II DIABETES WITH DIPEPTIDYL PEPTIDASE IV INHIBITORS
BR0308928A (en) Use of botulinum toxin for the treatment of cardiovascular disease, as well as composition for use in a cardiovascular procedure.
UA94899C2 (en) Fixed dosing of her antibodies
CY1112397T1 (en) COMBINED TREATMENT FOR CANCER
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
MY169308A (en) Treatment of tnf? related disorders
DK1373215T3 (en) Gelanamycin derivatives suitable for the treatment of cancer
BRPI0418745A (en) cell line antibody, pharmaceutical composition, and method of treating cancer in a patient
WO2004045507A3 (en) Anti-angiogenic uses of il-6 antagonists
NO20045056L (en) Methods for the treatment of hepatitis
EA201000630A1 (en) APPLICATION OF BENZO-CONDENSED HETERO-CYCLIC SULFAMIDE DERIVATIVES TO REDUCE LIPPLE LEVELS IN THE BLOOD
WO2002078639A3 (en) A method of treating proliferative diseases using eg5 inhibitors
ATE424208T1 (en) PROTEIN KINASE INHIBITORS
EA200700407A1 (en) HINAZOLIN DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOCYTHEMIA
DE60309887D1 (en) COMBINATION OF AN AROMATASE WITH A BISPHOSPHONATE
CY1108552T1 (en) THERAPEUTIC TREATMENT OF NON-ALCOHOLIC STEATHEPATIDAS (NASH)
DE602005020113D1 (en) METHOD FOR THE TREATMENT OF ACUTE RHINOSINUSITIS
MXPA05010216A (en) Use of ritonavir for the treatment of unconjugated hyperbilirubinemia.
MXPA05013975A (en) Treatment of amyloid- and epileptogenesis-associated diseases.
EA200600989A1 (en) APPLICATION OF GABOXADOL FOR THE TREATMENT OF CEREBELLS
DE60334289D1 (en) DITHIOLOPYRROLONE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISORDER
ATE537838T1 (en) COMBINATION THERAPY WITH KLORETAZINE(TM)
TW200512183A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of frailty, muscle damage or sarcopenia

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or assignment